Therapy Detail

Therapy Name BEZ235 + Doxorubicin
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Aldoxorubicin INNO-206|doxorubicin prodrug INNO-206 Chemotherapy - Anthracycline 11 Aldoxorubicin is a derivative prodrug of doxorubicin that is converted to free doxorubicin within the acidic environment within tumors. Once converted, doxorubicin intercalates DNA, inhibits DNA synthesis and induces apotosis (NCI Drug Dictionary).
BEZ235 NVP-BEZ235|Dactolisib ATR Inhibitor 9 mTOR Inhibitor 48 PI3K Inhibitor (Pan) 34 BEZ235 inhibits PI3K kinase, mTOR kinase, and ATR, which may result in tumor cell apoptosis and growth inhibition of tumor cells (PMID: 18606717, PMID: 21552262).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown leiomyosarcoma not applicable BEZ235 + Doxorubicin Preclinical Actionable In a preclinical study, the combination of doxorubicin and BEZ235 produced a synergistic effect in leiomyosarcoma cells both in culture and in mouse models, resulting in apoptotic induction and a 68% reduction in tumor volume (PMID: 26952093). 26952093
Clinical Trial Phase Therapies Title Recruitment Status